

# **RAFI™ Multi-Factor Climate Transition Index Series Attribution Summary: Q1 2024**

## Developed

Performance Analysis	QTD Return	QTD Excess Return	YTD Return	1-Year Return	Carbon Intensity (CF/EVIC)
RAFI Multi-Factor Climate Transition Developed Index	10.98%	2.03%	10.98%	23.85%	196.1
RAFI Multi-Factor ex Size Developed	10.00%	1.05%	10.00%	21.98%	928.6
<i>Solactive GBS Dev Markets Large/Mid Cap Index</i>	8.96%	---	8.96%	25.74%	521.6
Factor Attribution	QTD Return	QTD Excess Return	YTD Return	1-Year Return	Carbon Intensity (CF/EVIC)
RAFI Value Factor Developed	10.85%	1.9%	10.9%	24.07%	2179.8
RAFI Low Volatility Factor Developed	5.63%	-3.3%	5.6%	10.96%	393.8
RAFI Quality Factor Developed	7.43%	-1.5%	7.4%	19.78%	724.2
RA Momentum Factor Developed	14.20%	5.2%	14.2%	29.38%	607.7

The RAFI Multi-Factor Climate Transition Developed Index beat its cap-weight benchmark by 2.03% in Q1. The American economy continues to surprise to the upside, posting persistently stronger than expected employment and growth numbers. Downstream, American markets have broadened with the S&P EW index going on a surging run from November setting a new peak in the new year. Meanwhile, there has been increased dispersion among the Magnificent 7, as Nvidia and Meta charge ahead while Tesla and Apple lag the group and the broader market. As we have [warned](#), the last mile of inflation will be challenging for central banks to handle, driven organically by services and expectations as well as the simple mechanical process of how housing is captured by inflation measures. Internationally, market conditions are more mixed though surprisingly robust given geopolitical risks. European central banks look closer to easing while on the back of solid growth and strong governance reforms, Japan looks close to its first hikes in more than a decade. The speculative AI goldrush, valuations and geopolitical risk remain key themes to watch as the year develops.

The broadening of markets has played out in the strong performance in the momentum and value factor sleeves. Momentum posted strong excess returns, running ahead of the cap-weight benchmark by 524 bps. The value sleeve added 189 bps to excess return. This is notably in contrast to the MSCI World Value Index which lagged its Growth counterpart by 259 bps for the quarter. Low Volatility has continued to struggle to keep pace in this volatile and momentum-lead market, lagging the reference benchmark by 333 bps for the quarter. Quality trailed by 153 bps for the quarter.

The climate transition strategy outperformed a comparable unconstrained strategy by 98 bps in Q1 2024. The constrained strategy benefitted from significantly larger positions in Nvidia and Meta platforms relative to the unconstrained strategy. Nvidia and Meta contributed 89 bps and 81 bps, in excess returns relative to the unconstrained strategy. This was largely driven by their favorable

carbon profiles though the potential AI revolution may become more carbon intensive as it is realized. This has predictable consequences for relative positioning between strategies with a 6.35% overweight to the US relative to the unconstrained strategy and corresponding relative tilts into Communications and Technology.

## Stock Analysis

### Top Five/Bottom Five Contributors to Excess Return

	Total	Active	Q1 2024	Excess Return	Value	Initial Factor Sleeve Weights		
	Weight	Weight	Return	Contribution		Low Volatility	Quality	Momentum
<b>Top Five Contributors to Return</b>								
Meta Platforms	4.91%	3.30%	37.33%	0.80%	—	—	0.71%	0.76%
Eli Lilly	3.21%	2.22%	33.69%	0.48%	—	0.47%	0.46%	0.62%
Apple	2.38%	-2.10%	-10.82%	0.46%	—	—	0.64%	0.50%
Tesla	0.00%	-0.90%	-29.25%	0.45%	—	—	—	—
Novo Nordisk	2.21%	1.59%	24.24%	0.26%	—	0.31%	0.29%	0.24%
<b>Bottom Five Contributors to Return</b>								
Amazon	0.00%	-2.48%	18.72%	-0.23%	—	—	—	0.68%
Nvidia	2.55%	-0.26%	82.46%	-0.18%	—	—	—	0.83%
Microsoft	0.10%	-4.81%	12.09%	-0.16%	—	—	—	0.10%
Gilead Sciences	0.83%	0.67%	-8.64%	-0.13%	0.10%	0.35%	0.38%	—
Toyota	0.00%	-0.41%	38.12%	-0.11%	—	—	0.15%	0.17%

Note: RAFI Multi-Factor Climate Transition Index dynamically tilts securities weights as a function of carbon intensity. Sleeve weights may not perfectly map to the final portfolio weight.

Following a precipitous decline in 2022, Meta Platforms has bounced back on the impetus of a ‘year of efficiency’. A capable open-source AI program, stronger advertising conditions than expected and uncertainty surrounding rival Tiktok, all contributed to a stellar 2023 and the continued surging run in 2024, up 37.3% in Q1. The strategy took on exposure to Meta through the quality and momentum sleeves with the carbon tilt process leaning into Meta. The 3.3% overweight to Meta added 80 bps to excess returns. Eli Lilly enjoyed a strong Q1 up 33.69%, with bullish expectations for its Ozempic weight-loss competitor. The strategy took on exposure through the low volatility, quality and momentum sleeves with a strong increase in weighting driven by favorable carbon characteristics. The strategy’s 2.22% overweight to Eli Lilly added 48 bps to performance. American mega-caps Apple (-2.10% active weight) and Tesla (-0.90% active weight) each contributed to performance through a systematic underweight, adding 46 bps and 45 bps, respectively to performance, as Apple stumbled and Tesla toppled over in Q1.

Detractors were relatively diffuse and limited in size, with the portfolio largely underweighting mega-cap AI themes. Amazon has seen a moderate boom this year, benefiting from flows into the cloud infrastructure that would support an AI revolution. The -2.48% underweight to Amazon detracted 23 bps from performance. Notably relative to the unconstrained version, the RAFI Multi-Factor Climate

Transition Index’s carbon tilt resulted in a larger allocation and consequently smaller 0.26% underweight to Nvidia. Nvidia left the rest of the Magnificent 7 in the dust, running up 82.46% this quarter, removing 18 bps from performance. Nvidia enters the portfolio through the momentum sleeve.

## Sector Analysis

12/29/2023 to 3/28/2024	RAFI Multi-Factor Climate Transition Developed Index		Solactive GBS Developed Markets Large & Mid Cap Index		Attribution Analysis		
	Port. Average Weight	Port. Total Return	Bench. Average Weight	Bench. Total Return	Allocation Effect	Selection + Interaction	Total Effect
<b>Total</b>	<b>100.00</b>	<b>10.79</b>	<b>100.00</b>	<b>8.90</b>	<b>-0.13</b>	<b>2.02</b>	<b>1.89</b>
<b>Basic Materials</b>	4.09	4.28	4.06	3.71	-0.00	0.02	0.02
<b>Communications</b>	10.68	20.71	7.95	13.15	0.05	0.68	0.74
<b>Consumer Cyclical</b>	10.23	7.45	10.43	7.13	0.01	0.03	0.04
<b>Consumer Non-Cyclical</b>	9.53	3.77	7.07	4.06	-0.12	-0.03	-0.15
<b>Energy</b>	1.91	6.78	4.33	9.39	-0.02	-0.05	-0.07
<b>Financials</b>	11.58	11.38	13.46	10.52	-0.05	0.10	0.05
<b>Healthcare</b>	19.69	11.56	12.28	7.77	-0.09	0.75	0.65
<b>Industrial</b>	9.23	6.98	10.01	8.85	-0.00	-0.18	-0.18
<b>Real Estate</b>	0.79	5.33	2.11	-0.01	0.12	0.04	0.16
<b>Technology</b>	21.12	15.33	25.86	11.92	-0.14	0.71	0.58
<b>Utilities</b>	1.16	-3.75	2.43	0.72	0.11	-0.06	0.06

At the sector level, security selection rather than allocation decisions drove the bulk of performance, accounting for 202 bps of the total 189 bps in excess returns. Communications (2.73% active weight) was the greatest source of returns, adding 74 bps to performance, driven predominantly by positioning in Meta. Healthcare was the next greatest segment with a 7.41% overweight translating to 65 bps in excess returns. Selection effects explained 75 bps of the total 65 bps in excess returns as the sector as a whole lagged the broader index. Within Healthcare, obesity drug innovators Eli Lilly (2.22% active weight) and Novo Nordisk (1.59% active weight) added 48 bps and 26 bps, respectively. Both have been boosted by expectations that public insurance in the US will cover their new obesity drugs. Technology contributed 58 bps to performance from a -4.74% underweight. The -2.10% underweight to apple added 46 bps to excess returns.

## Geographic Analysis

12/29/2023 to 3/28/2024	RAFI Multi-Factor Climate Transition Developed Index		Solactive GBS Developed Markets Large & Mid Cap Index		Attribution Analysis		
	Port. Average Weight	Port. Total Return	Bench. Average Weight	Bench. Total Return	Allocation Effect	Selection + Interaction	Total Effect
<b>Total</b>	<b>100.00</b>	<b>10.79</b>	<b>100.00</b>	<b>8.90</b>	<b>-0.11</b>	<b>2.00</b>	<b>1.89</b>
<b>Developed Asia Pacific x JP</b>	2.25	0.57	3.11	-2.40	0.10	0.07	0.17
<b>Europe - Non-EU</b>	7.39	7.76	4.51	3.49	-0.15	0.34	0.18
<b>European Union</b>	10.53	8.00	9.10	8.30	-0.01	-0.03	-0.04
<b>Japan</b>	8.94	7.77	6.98	10.42	0.05	-0.24	-0.19
<b>United Kingdom</b>	4.76	4.41	3.84	3.06	-0.06	0.07	0.01
<b>United States</b>	63.04	13.55	68.51	10.44	-0.09	1.89	1.81
<b>Other Developed</b>	3.09	0.45	3.58	3.56	0.03	-0.10	-0.08
<b>Other</b>	--	--	0.17	-0.58	0.02	--	0.02
<b>[Unassigned]</b>	--	--	0.20	3.50	0.01	--	0.01

Breaking out performance by region, performance was once again largely driven by security selection rather than allocation effects (selection effects accounted for 200 bps of the total 189 bps in excess return.) The strategy saw its largest contribution to excess return from the US (-5.47% active weight) with the segment accounting for 181 bps in excess return. Positioning in Eli Lilly and American mega-cap technology firms such as Meta, Apple and Tesla, drove performance in the region. The strategy also saw a contribution of 18bps to excess return from non-EU Europe (2.88% active weight). The overweight to Novo Nordisk accounted the bulk of excess performance within the region. The strategy lagged in Japan (1.96% active weight) with security selection detracting -24 bps of a total -19 bps deduction from performance from the country. Performance in Japan was driven by a -0.41% underweight to Toyota Motors, which detracted 11 bps from performance. The strategy leaned out of Toyota Motors due to its ESG constraints.

## Rebalance Analysis

The following table lists the top five largest stocks by cap-weight that failed to make it into the index at the 3/15/2024 rebalance due to their factor scores or carbon tilting. Cumulative-weight rank represents each stock's position by weight within each factor sleeve prior to selection; value, low volatility, and quality select the top 25% of stocks by RAFI weight, and momentum selects the top 50% of stocks by market capitalization. Exxon Mobil and Berkshire Hathaway notably qualify for our standard RAFI Multi-Factor strategy but are excluded from the CTI index due to their carbon intensity.

Company	Region	Cap-Weight (3/31/2024)	Cumulative Weight Rank			
			Value	Low Volatility	Quality	Momentum
Amazon	US	2.57%	92.5%	46.4%	95.9%	13.5%
Berkshire Hathaway	US	0.86%	56.2%	23.5%	84.4%	25.1%
Tesla, Inc.	US	0.76%	99.4%	95.4%	97.3%	76.4%
Exxon Mobil	US	0.74%	15.9%	85.1%	49.4%	94.0%
UnitedHealth	US	0.73%	65.6%	28.2%	78.6%	71.9%

## Important Information

The material contained in this document is for informational purposes only. This material is not intended as an offer or solicitation for the purchase or sale of any security or financial instrument, nor is it advice or a recommendation to enter into any transaction. RAFI Indices, LLC ("RI"), its affiliates, agents, and each of their respective officers, directors, employees, agents, representatives and licensors (collectively "Research Affiliates") does not make any warranties, express or implied, to anyone regarding the information provided herein, including, without limitation, any warranties with respect to the timeliness, sequence, accuracy, completeness, currentness, merchantability, quality or fitness for a particular purpose or any warranties as to the results to be obtained by any third-party in connection with the use of the information. Nothing contained in this material is intended to constitute legal, tax, securities or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained in this material should not be acted upon without obtaining specific legal, tax and investment advice from a registered professional. Investors should be aware of the risks associated with data sources and quantitative processes used to create the content contained herein or the investment management process. Errors may exist in data acquired from third party vendors, the construction or coding of indices or model portfolios, and the construction of the spreadsheets, results or information provided. Research Affiliates takes reasonable steps to eliminate or mitigate errors, and to identify data and process errors so as to minimize the potential impact of such errors, however Research Affiliates cannot guarantee that such errors will not occur. Use of this material is conditioned upon, and evidence of, the user's full release of Research Affiliates from any liability or responsibility for any loss or damage, direct, indirect or consequential, arising from or related to (i) any inaccuracy or incompleteness in, errors or omissions in the information or (ii) any decision made or action taken by any third party in reliance upon this information. Research Affiliates shall not be liable to anyone for loss of business revenues, lost profits or any indirect, consequential, special or similar damages whatsoever, whether in contract, tort or otherwise, even if advised of the possibility of such damages.

Past performance is not indicative of future results. Certain performance information presented represents simulated performance or performance based on combined simulated index data (pre-index launch) and live index data (post-index launch). Past simulated performance is no guarantee of future performance and does not represent actual performance of an investment product based on an index. No allowance has been made for trading costs, management fees, or other costs associated with asset management, as the information provided relates only to the index itself. Performance data includes reinvestment of all dividends and income. Indexes are unmanaged and cannot be invested in directly. Actual investment results will differ. The simulated data may have under- or over-compensated for the impact, if any, of certain market factors. Simulated returns may not reflect the impact that material economic and market factors might have had on an investor's decision making. Simulated data is subject to the fact that it is designed with the benefit of hindsight. Simulated returns carry the risk that actual performance is not as depicted is not due to inaccurate predictive modeling. Simulated returns cannot predict how an investment strategy will perform in the future. Investors may experience loss of all or some of their investment.

Any applicable financial instruments are not sponsored, promoted, sold or supported in any other manner by RI or Solactive AG nor does RI or Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trade mark or the Index Price at any time or in any other respect. The Index is calculated and published by RI and Solactive AG. RI and Solactive AG use their best efforts to ensure that the Index is calculated correctly. Irrespective of their obligations towards Licensee, neither RI nor Solactive AG has any obligation to point out errors in the Index to third parties including but not limited to Licensee, investors and/or financial intermediaries of the financial instrument. Neither publication of the Index nor the licensing of the Index or Index trade mark for the purpose of use in connection with the financial instrument constitutes a recommendation by RI or Solactive AG to invest capital in said financial instrument nor does it in any way represent an assurance or opinion of RI or Solactive AG with regard to any investment in the financial instrument.

The trademarks Fundamental Index™, RAFI™, Research Affiliates Equity™, RAE™ and the Research Affiliates™ trademark and corporate name and all related logos are the exclusive intellectual property of Research Affiliates, LLC ("RA") and in some cases are registered trademarks in the U.S. and other countries. Various features of the Fundamental Index methodology, including an accounting data-based non-capitalization data processing system and method for creating and weighting an index of securities, are protected by various patents of RA. (See applicable US Patents, Patent Publications and protected trademarks located at <https://www.researchaffiliates.com/legal/disclosures#patent-trademarks-and-copyrights>, which are fully incorporated herein.) Any use of these trademarks, logos or patented methodologies without the prior written permission of RA is expressly prohibited. RA reserves the right to take any and all necessary action to preserve all of its rights, title, and interest in and to these marks or patents.

RI does not offer or provide investment advice or offer or sell any securities, commodities or derivative instruments or products. Any such business may only be conducted through registered or licensed entities and individuals permitted to do so within the respective jurisdiction and only in conjunction with the legally required disclosure documents and regulatory filings.

© 2024 RAFI Indices, LLC. All rights reserved. Duplication or dissemination prohibited without prior written permission.